{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:20:53Z","timestamp":1793985653577,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032339","name":"BioNTech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.isci.2026.116022","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:39:03Z","timestamp":1781224743000},"page":"116022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity"],"prefix":"10.1016","volume":"29","author":[{"given":"Sven","family":"Kratochvil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Sayettat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Janaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pra\u00dfl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Stumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Kn\u00fcfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Tolksdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Malz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinethemba","family":"Bhebhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonhlanhla","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Le Douce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116022_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708227","article-title":"To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1","volume":"12","author":"Griffith","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116022_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review","volume":"22","author":"Mahomed","year":"2025","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.isci.2026.116022_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116022_bib4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"Gilbert","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.116022_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2026.116022_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","article-title":"Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering","volume":"35","author":"Ko","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.isci.2026.116022_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.710044","article-title":"Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?","volume":"12","author":"Hsu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116022_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.116022_bib9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116022_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.116022_bib11","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116022_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011469","article-title":"Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials","volume":"19","author":"Mkhize","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.116022_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2484443","article-title":"Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice","volume":"17","author":"Haraya","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2026.116022_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40259-022-00566-2","article-title":"Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations","volume":"37","author":"Haraya","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.isci.2026.116022_bib15","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","article-title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies","volume":"8","author":"Avery","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2026.116022_bib16","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/19420862.2016.1229721","article-title":"Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics","volume":"8","author":"Myzithras","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2026.116022_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/19420862.2018.1462429","article-title":"Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach","volume":"10","author":"Betts","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2026.116022_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050594","article-title":"Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV","volume":"16","author":"Mayer","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2026.116022_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116022_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143958","article-title":"Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention","volume":"6","author":"Kisalu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.116022_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004329","article-title":"Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127\/HPTN 087): A Phase I randomized clinical trial","volume":"21","author":"Walsh","year":"2024","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2026.116022_bib22","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2352-3018(25)00041-4","article-title":"Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults","volume":"12","author":"Wu","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.isci.2026.116022_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581153","article-title":"Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform","volume":"16","author":"Grudzinska-Goebel","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116022_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181496","article-title":"Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection","volume":"10","author":"Happe","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.116022_bib25","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.116022_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01909-20","article-title":"Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates","volume":"95","author":"Lorenzi","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116022_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00008-25","article-title":"Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies","volume":"99","author":"Sutar","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116022_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/COH.0000000000000368","article-title":"Progress in HIV-1 antibody research using humanized mice","volume":"12","author":"Gruell","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.isci.2026.116022_bib29","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1128\/JVI.76.12.6332-6343.2002","article-title":"Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116022_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/2472555219897567","article-title":"New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening","volume":"25","author":"Freeth","year":"2020","journal-title":"SLAS Discov."},{"key":"10.1016\/j.isci.2026.116022_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.isci.2026.116022_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jviromet.2007.02.015","article-title":"High throughput functional analysis of HIV-1 env genes without cloning","volume":"143","author":"Kirchherr","year":"2007","journal-title":"J. Virol. Methods"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226013970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226013970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:00:12Z","timestamp":1791838812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226013970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589004226013970"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116022","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116022"}}